UNIVERSAL HEALTH REALTY INCOME TRUST (UHT)·Q2 2025 Earnings Summary
Executive Summary
- Q2 2025 delivered modest topline growth but earnings compression: revenue rose slightly y/y and q/q to $24.9M while diluted EPS fell to $0.32 (vs. $0.38 y/y; $0.34 q/q) on higher interest expense and lack of the prior-year one-time property tax benefit .
- FFO was $11.8M ($0.85/share), down from $12.4M ($0.90/share) y/y and down a penny q/q, reflecting softer net income partially offset by higher depreciation and amortization .
- Liquidity remains solid: $354.8M outstanding on the $425M revolver and $70.2M of availability at 6/30/25; maturity in 2028 with two optional six‑month extensions .
- Dividend increased by $0.005 to $0.74/share in June, continuing the REIT’s dividend growth cadence; paid June 30, 2025 .
- No earnings call transcript or guidance found for Q2; narrative focus stayed on rate sensitivity and tenant operating cost pressures—key drivers of sentiment and estimate risk near term .
What Went Well and What Went Wrong
- What Went Well
- Stable rental engine: Total revenues ticked up to $24.9M (+0.5% y/y; +1.3% q/q), with non‑related party lease revenue slightly higher and bonus rent at McAllen Medical Center increasing y/y ($862K vs $758K) .
- Dividend growth continues: Board raised the quarterly dividend to $0.74/share (from $0.735), paid June 30, reinforcing income appeal .
- Ample liquidity runway: $70.2M of revolver availability and 2028 maturity provide balance sheet flexibility amid a high-rate environment .
- What Went Wrong
- Earnings pressure: Diluted EPS fell to $0.32 on higher interest expense (+$137K impact y/y) and cycling out a $563K prior-year property tax benefit; FFO/share declined to $0.85 (from $0.90) .
- Margin compression: Net income margin and EBIT margin trended lower vs both Q1 and prior year as rate costs and property-level variances weighed (see margin table) .
- No guidance and limited qualitative detail: The company furnished the press release via 8‑K, but no Q2 call transcript was found; macro/tenant cost risks remain highlighted without quantified outlook .
Financial Results
Revenue, EPS, FFO (oldest → newest)
Margins (S&P Global) (oldest → newest)
Values retrieved from S&P Global.*
Revenue composition (oldest → newest)
Liquidity and capital (oldest → newest)
Guidance Changes
No revenue, margin, OpEx, tax, or segment guidance was provided in the Q2 2025 materials reviewed .
Earnings Call Themes & Trends
No Q2 2025 earnings call transcript was found in our document catalog for June–August 2025. The thematic analysis below draws from the past three press releases.
Management Commentary
- “For the three-month period ended June 30, 2025, net income was $4.5 million, or $.32 per diluted share, as compared to $5.3 million, or $.38 per diluted share, during the second quarter of 2024.”
- “Our funds from operations (‘FFO’) were $11.8 million, or $.85 per diluted share, during the second quarter of 2025, as compared to $12.4 million, or $.90 per diluted share, during the second quarter of 2024.”
- “As of June 30, 2025, pursuant the terms of our $425 million credit agreement… we had $70.2 million of available borrowing capacity, net of $354.8 million of borrowings.”
- Risk framing: Management highlights sustained rate pressure, tenant staffing cost risks, and potential Medicaid/regulatory headwinds as key exogenous factors affecting results and tenant health .
Q&A Highlights
No Q2 2025 earnings call transcript was available in our catalog; the company furnished the press release via an 8‑K but we found no call materials for this period . Accordingly, there were no public Q&A clarifications to supplement the press release.
Estimates Context
- S&P Global consensus: We did not find Q2 2025 consensus for EPS or revenue (no values returned; # of estimates unavailable). As a result, a beat/miss vs. consensus cannot be determined for this quarter. Values retrieved from S&P Global.
- Reported actuals: Revenue $24.9M and diluted EPS $0.32 for Q2 2025 per company release .
Key Takeaways for Investors
- Defensive revenue base, but earnings sensitivity to rates persists: modest revenue growth contrasted with EPS/FFO/share slippage as funding costs rose and a prior-year tax benefit rolled off .
- Dividend compounding intact: incremental raise to $0.74 demonstrates confidence in cash flow stability despite margin pressure; income investors likely to view the cadence favorably .
- Liquidity and duration buy time: $70.2M of revolver availability and 2028 maturity provide operating flexibility to manage through higher rates and tenant cost pressures .
- Margin trajectory bears watching: EBIT and net margins compressed sequentially and y/y; further rate relief or tenant operating normalization would be catalysts for re‑expansion (see margin table).*
- Limited disclosure (no call) concentrates focus on hard metrics: without guidance, investors should track quarterly revenue run‑rate, FFO/share, and revolver usage for trend confirmation .
- Property-level levers: Bonus rent and mix of UHS vs. third‑party leases remained constructive; watch for leasing progress and disposition updates on legacy assets to aid NOI stability .
- Near‑term trading setup: Dividend support and stable revenue can anchor downside, but lack of estimate visibility and margin headwinds may cap upside until rate backdrop eases or tenant cost pressures abate .
Values retrieved from S&P Global.*